VECTIBIX 100MG INJ VIAL

About

Vectibix 100mg Injection is a monoclonal antibody, specifically an epidermal growth factor receptor (EGFR) inhibitor, used in the treatment of metastatic colorectal cancer (mCRC). It works by binding to the EGFR on the surface of cancer cells, thereby blocking the activation of signaling pathways that promote cell growth, proliferation, and survival. This targeted action leads to the inhibition of tumor growth and can induce apoptosis (programmed cell death) in cancer cells that overexpress EGFR. Vectibix is typically administered intravenously and is often used in patients whose tumors are wild-type RAS (i.e., without mutations in KRAS or NRAS genes), as these patients are more likely to respond to EGFR-targeted therapy.

It is often used as a monotherapy or in combination with chemotherapy regimens, particularly after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The treatment aims to extend progression-free survival and overall survival, improving the quality of life for patients with advanced colorectal cancer. Close monitoring for infusion-related reactions and dermatological toxicities is essential during therapy.

Uses

• Treatment of metastatic colorectal cancer (mCRC).
• Used in patients with wild-type RAS mCRC.
• Monotherapy after failure of prior chemotherapy.
• In combination with specific chemotherapy regimens.

Directions For Use

Administered intravenously by a healthcare professional in a clinical setting. Dosage and frequency are determined by the physician based on patient weight and condition.

Benefits

• Targets and inhibits cancer cell growth.
• Extends progression-free survival in mCRC.
• Improves overall survival in selected patients.
• Effective in wild-type RAS metastatic colorectal cancer.
• Can be used as monotherapy or in combination.
• Offers a targeted approach to cancer treatment.

Side Effects

• Skin rash (acneiform dermatitis)
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Hypomagnesemia
• Infusion-related reactions
• Paronychia (nail inflammation)
• Dry skin
• Conjunctivitis
• Pulmonary fibrosis (rare)
• Electrolyte disturbances

Safety Measures

• Alcohol - No direct interaction, but alcohol consumption should be limited as it can worsen general health and potentially interact with other co-administered medications.
• Pregnancy - Contraindicated. Can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 2 months after the last dose.
• Breastfeeding - Contraindicated. It is unknown if it is excreted in human milk; due to potential harm to the infant, breastfeeding should be discontinued during treatment and for 2 months after the last dose.
• Liver - Use with caution in patients with severe hepatic impairment; monitor liver function tests regularly.
• Kidney - Use with caution in patients with severe renal impairment; monitor kidney function tests regularly.
• Lung - Use with extreme caution in patients with pre-existing interstitial lung disease or pulmonary fibrosis, as it can exacerbate or induce severe lung toxicity.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.